Deutsche Bank raised the firm’s price target on Novartis (NVS) to CHF 125 from CHF 120 and keeps a Buy rating on the shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Novartis receives FDA Breakthrough Therapy designation for ianalumab
- Trump Trade: White House releases details on ‘Great Healthcare Plan’
- Drugmakers concerned about legal risk with FDA review program, Reuters reports
- Novartis: Buy Rating Backed by Strong Rx Momentum, De-Risked Late-Stage Pipeline and Attractive Valuation
- White House releases details on Trump ‘Great Healthcare Plan’